Table 1.
Effects of therapy with GHRH antagonists JMR-132 and docetaxel alone and their combinations on the growth of MX-1 human breast cancer xenografted into nude mice
| Treatment | Initial tumor volume, mm3 | Final tumor volume, mm3 (% inhibition) | Tumor weight, mg (% inhibition) | Tumor doubling time, days | Body weight on day 24, g |
|---|---|---|---|---|---|
| Control | 77.2 ± 5.6 | 1,478.1 ± 286.5 | 1,720.9 ± 352.4 | 6.0 ± 0.5 | 26.3 ± 1.3 |
| JMR-132 at 10 μg/day | 71.2 ± 5.6 | 547.3 ± 88.1 (62.9)* | 899.1 ± 152.5 (47.8)* | 7.9 ± 0.6* | 24.6 ± 1.3 |
| Docetaxel at 20 milligrams per kilogram of body weight | 76.9 ± 9.2 | 382.2 ± 57.5 (74.1)** | 712.7 ± 263.9 (58.6)* | 10.3 ± 0.9** | 24.0 ± 1.4 |
| Docetaxel and JMR-132 | 69.1 ± 6.4 | 33.7 ± 14.3 (97.7)** | 75.0 ± 35.2 (95.6)** | NC | 21.7 ± 1.5 |
NC, not calculated.
*, P < 0.05
**, P < 0.001 vs. control.